Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

DFE Pharma expands its C2F Center of Excellence in Hyderabad to advance the development of critical respiratory treatments

Our Bureau, Mumbai
Tuesday, January 14, 2025, 09:00 Hrs  [IST]

DFE Pharma, a global leader in pharmaceutical and biopharmaceutical excipient solutions, has expanded the capabilities of its Closer to the Formulator (C2F) Center of Excellence located in Genome Valley, Hyderabad. This significant investment has enabled the company to offer specialized analytical services for dry powder inhalation (DPI) dosage forms, addressing the growing demand for effective respiratory treatments.

Since its opening in September 2022, the C2F centre supports global pharmaceutical companies to bring their products to market faster and more efficiently. The centre's expertise lies in all phases of pharmaceutical development, initially focused on oral solid dosage (OSD), now has also extended its scope to inhaled forms.

Given the complexity of developing DPI formulations and the increasing importance of speed to market, DFE Pharma aims to ease and accelerate inhaled product development. To achieve this, the Center of Excellence now offers analytical method development, reference listed drug (RLD) characterization, stability studies, and realistic lung deposition in-vitro techniques to enhance In-Vitro In-Vivo correlation (IVIVC). Additionally, with a dedicated team of inhalation specialists, the C2F centre provides cutting-edge capabilities available only in few laboratories worldwide, such as anatomical throats and respiratory dissolution profiles endorsed by the FDA. These techniques shorten project timelines by minimizing the need for multiple pilot pharmacokinetic studies.

"We are thrilled to announce this expansion of our C2F Center of Excellence," said Dr. Anilkumar Gandhi, director of the C2F Center of Excellence. “With this investment in DPI expertise, we will support global customers working on inhaled products development, to bring drugs to market quickly and cost-effectively.”

This investment to add analytical services for DPI dosage forms, reinforces DFE Pharma’s long-term commitment to the Genome Valley and Hyderabad region, and represents a significant step forward in the company’s mission to provide innovative solutions to the global pharmaceutical industry.
 
DFE Pharma is a global leader in pharma- and nutraceutical excipient solutions. We develop, produce and supply high-quality functional excipients for use in the pharmaceutical, biopharmaceutical, and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
Asia_Lab_Expo2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram